FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081113288> ?p ?o ?g. }

• W3081113288 endingPage "5859" @default.
• W3081113288 startingPage "5852" @default.
• W3081113288 abstract "Abstract Purpose: Spleen tyrosine kinase (SYK) signaling is a proposed target in acute myeloid leukemia (AML). Sensitivity to SYK inhibition has been linked to HOXA9 and MEIS1 overexpression in preclinical studies. This trial evaluated the safety and efficacy of entospletinib, a selective inhibitor of SYK, in combination with chemotherapy in untreated AML. Patients and Methods: This was an international multicenter phase Ib/II study, entospletinib dose escalation (standard 3+3 design between 200 and 400 mg twice daily) + 7+3 (cytarabine + daunorubicin) in phase Ib and entospletinib dose expansion (400 mg twice daily) + 7+3 in phase II. Results: Fifty-three patients (n = 12, phase Ib and n = 41, phase II) with previously untreated de novo (n = 39) or secondary (n = 14) AML were enrolled (58% male; median age, 60 years) in this study. The composite complete response with entospletinib + 7+3 was 70%. Patients with baseline HOXA9 and MEIS1 expression higher than the median had improved overall survival compared with patients with below median HOXA9 and MEIS1 expression. Common adverse events were cytopenias, febrile neutropenia, and infection. There were no dose-limiting toxicities. Entospletinib-related skin rash and hyperbilirubinemia were also observed. Conclusions: Entospletinib with intensive chemotherapy was well-tolerated in patients with AML. Improved survival was observed in patients with HOXA9/MEIS1 overexpression, contrasting published data demonstrating poor survival in such patients. A randomized study will be necessary to determine whether entospletinib was a mediator this observation." @default.
• W3081113288 created "2020-09-01" @default.
• W3081113288 creator A5000921376 @default.
• W3081113288 creator A5004524654 @default.
• W3081113288 creator A5015273169 @default.
• W3081113288 creator A5023917898 @default.
• W3081113288 creator A5026397928 @default.
• W3081113288 creator A5034265050 @default.
• W3081113288 creator A5035236340 @default.
• W3081113288 creator A5040073166 @default.
• W3081113288 creator A5044042347 @default.
• W3081113288 creator A5050633601 @default.
• W3081113288 creator A5056698355 @default.
• W3081113288 creator A5059055898 @default.
• W3081113288 creator A5061736172 @default.
• W3081113288 creator A5066306425 @default.
• W3081113288 creator A5077113191 @default.
• W3081113288 creator A5080781659 @default.
• W3081113288 creator A5086016311 @default.
• W3081113288 creator A5086687120 @default.
• W3081113288 date "2020-11-13" @default.
• W3081113288 modified "2023-10-09" @default.
• W3081113288 title "Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <i>HOXA9</i> and <i>MEIS1</i> Expression" @default.
• W3081113288 cites W1965027324 @default.
• W3081113288 cites W1976172063 @default.
• W3081113288 cites W1978719672 @default.
• W3081113288 cites W1982113493 @default.
• W3081113288 cites W2034876218 @default.
• W3081113288 cites W2051815726 @default.
• W3081113288 cites W2063915767 @default.
• W3081113288 cites W2069457631 @default.
• W3081113288 cites W2095726706 @default.
• W3081113288 cites W2116858301 @default.
• W3081113288 cites W2135031820 @default.
• W3081113288 cites W2148047805 @default.
• W3081113288 cites W2159507916 @default.
• W3081113288 cites W2261591721 @default.
• W3081113288 cites W2339658711 @default.
• W3081113288 cites W2462207007 @default.
• W3081113288 cites W2546247047 @default.
• W3081113288 cites W2607287498 @default.
• W3081113288 cites W2770656572 @default.
• W3081113288 cites W2806039308 @default.
• W3081113288 cites W2892009646 @default.
• W3081113288 cites W4376595466 @default.
• W3081113288 doi "https://doi.org/10.1158/1078-0432.ccr-20-1064" @default.
• W3081113288 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32820015" @default.
• W3081113288 hasPublicationYear "2020" @default.
• W3081113288 type Work @default.
• W3081113288 sameAs 3081113288 @default.
• W3081113288 citedByCount "28" @default.
• W3081113288 countsByYear W30811132882020 @default.
• W3081113288 countsByYear W30811132882021 @default.
• W3081113288 countsByYear W30811132882022 @default.
• W3081113288 countsByYear W30811132882023 @default.
• W3081113288 crossrefType "journal-article" @default.
• W3081113288 hasAuthorship W3081113288A5000921376 @default.
• W3081113288 hasAuthorship W3081113288A5004524654 @default.
• W3081113288 hasAuthorship W3081113288A5015273169 @default.
• W3081113288 hasAuthorship W3081113288A5023917898 @default.
• W3081113288 hasAuthorship W3081113288A5026397928 @default.
• W3081113288 hasAuthorship W3081113288A5034265050 @default.
• W3081113288 hasAuthorship W3081113288A5035236340 @default.
• W3081113288 hasAuthorship W3081113288A5040073166 @default.
• W3081113288 hasAuthorship W3081113288A5044042347 @default.
• W3081113288 hasAuthorship W3081113288A5050633601 @default.
• W3081113288 hasAuthorship W3081113288A5056698355 @default.
• W3081113288 hasAuthorship W3081113288A5059055898 @default.
• W3081113288 hasAuthorship W3081113288A5061736172 @default.
• W3081113288 hasAuthorship W3081113288A5066306425 @default.
• W3081113288 hasAuthorship W3081113288A5077113191 @default.
• W3081113288 hasAuthorship W3081113288A5080781659 @default.
• W3081113288 hasAuthorship W3081113288A5086016311 @default.
• W3081113288 hasAuthorship W3081113288A5086687120 @default.
• W3081113288 hasBestOaLocation W30811132881 @default.
• W3081113288 hasConcept C126322002 @default.
• W3081113288 hasConcept C143998085 @default.
• W3081113288 hasConcept C170493617 @default.
• W3081113288 hasConcept C197934379 @default.
• W3081113288 hasConcept C2776611710 @default.
• W3081113288 hasConcept C2776694085 @default.
• W3081113288 hasConcept C2777063308 @default.
• W3081113288 hasConcept C2778041864 @default.
• W3081113288 hasConcept C2778336483 @default.
• W3081113288 hasConcept C2778570526 @default.
• W3081113288 hasConcept C2778729363 @default.
• W3081113288 hasConcept C2778850193 @default.
• W3081113288 hasConcept C31760486 @default.
• W3081113288 hasConcept C35174551 @default.
• W3081113288 hasConcept C42362537 @default.
• W3081113288 hasConcept C71924100 @default.
• W3081113288 hasConcept C90924648 @default.
• W3081113288 hasConceptScore W3081113288C126322002 @default.
• W3081113288 hasConceptScore W3081113288C143998085 @default.
• W3081113288 hasConceptScore W3081113288C170493617 @default.
• W3081113288 hasConceptScore W3081113288C197934379 @default.
• W3081113288 hasConceptScore W3081113288C2776611710 @default.
• W3081113288 hasConceptScore W3081113288C2776694085 @default.

• next